Projecting Introduction Timelines for Cholera Conjugate Vaccine and Typhoid-Cholera Conjugate Combo Vaccine: A Scenario-Based Forecasting Approach

Objective: This study aimed to project introduction timing and pathways of cholera conjugate vaccine (CCV) and combined typhoid-cholera conjugate vaccines (TCV/CCVs) in 39 low- and middle-income countries and to assess potential barriers to their routine immunization integration. Methods: Accelerated failure time models were fitted using oral cholera vaccine (OCV) introduction as a proxy for CCV adoption. Country-level estimates were standardized using observed post-WHO-prequalification introduction intervals for analogous vaccine transitions. TCV/CCV introduction timing and pathways were projected by combining standardized CCV estimates with a TCV introduction priority index based on typhoid burden and previous vaccination experience. Potential barriers to routine immunization integration were assessed using semi-quantitative scoring approach. Results: Gavi, the Vaccine Alliance (Gavi) eligibility, greater previous OCV experience, and higher cholera intensity were associated with earlier introduction times. After standardization, the median projected time to CCV introduction was 6.9 years after WHO prequalification, with 12 countries introducing within five years. The TCV/CCV projections comprised three pathways: CCV introduction followed by transition to TCV/CCV, direct TCV/CCV introduction and continued CCV use without TCV/CCV introduction during the analysis period. Projected introduction timing was not consistently aligned with routine integration barrier levels for either vaccine. Conclusions: These scenario-based projections provide an early indication of where and when demand may emerge and which countries may require additional programmatic or financing support. The findings can inform demand forecasting, market assessment, manufacturing and supply planning, investment decisions, and introduction preparedness, but the projections should be recalibrated as product-specific evidence becomes available.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-12
DOI
https://doi.org/10.64898/2026.11.09.26367688
Primary Topic
Vibrio bacteria research studies
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Projecting Introduction Timelines for Cholera Conjugate Vaccine and Typhoid-Cholera Conjugate Combo Vaccine: A Scenario-Based Forecasting Approach

Victor Raynaud, Wongyeong Choi, Yunjin Yum, Julia A. Lynch et al.
medRxiv
Vibrio bacteria research studies
preprint

Projecting Introduction Timelines for Cholera Conjugate Vaccine and Typhoid-Cholera Conjugate Combo Vaccine: A Scenario-Based Forecasting Approach

Victor Raynaud, Wongyeong Choi, Yunjin Yum, Julia A. Lynch, Jung-Seok Lee, Yongha Hwang
preprint en

Abstract

Objective: This study aimed to project introduction timing and pathways of cholera conjugate vaccine (CCV) and combined typhoid-cholera conjugate vaccines (TCV/CCVs) in 39 low- and middle-income countries and to assess potential barriers to their routine immunization integration. Methods: Accelerated failure time models were fitted using oral cholera vaccine (OCV) introduction as a proxy for CCV adoption. Country-level estimates were standardized using observed post-WHO-prequalification introduction intervals for analogous vaccine transitions. TCV/CCV introduction timing and pathways were projected by combining standardized CCV estimates with a TCV introduction priority index based on typhoid burden and previous vaccination experience. Potential barriers to routine immunization integration were assessed using semi-quantitative scoring approach. Results: Gavi, the Vaccine Alliance (Gavi) eligibility, greater previous OCV experience, and higher cholera intensity were associated with earlier introduction times. After standardization, the median projected time to CCV introduction was 6.9 years after WHO prequalification, with 12 countries introducing within five years. The TCV/CCV projections comprised three pathways: CCV introduction followed by transition to TCV/CCV, direct TCV/CCV introduction and continued CCV use without TCV/CCV introduction during the analysis period. Projected introduction timing was not consistently aligned with routine integration barrier levels for either vaccine. Conclusions: These scenario-based projections provide an early indication of where and when demand may emerge and which countries may require additional programmatic or financing support. The findings can inform demand forecasting, market assessment, manufacturing and supply planning, investment decisions, and introduction preparedness, but the projections should be recalibrated as product-specific evidence becomes available.

medRxiv
International Vaccine Institute (KR), Gavi (CH)
Good health and well-being
Vibrio bacteria research studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon